Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06639477

Assessing Improvements in Mood and Sleep Trial

This is a multi-site randomized control trial involving people age 55+ years who have current depression symptoms plus another suicide risk indicator (either current suicidal ideation or a past history of attempt). Our goal is evaluate which of two different approaches works best to improve things like trouble sleeping, bad moods, and any suicidality.

Participants will complete diagnostic interviews, self-report scales, and wear an actigraphy device for the 8 weeks starting at the baseline visit.

Recruiting

Interested in participating?

Request Info

Key information

Age range

55 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The Regents of the University of California, Los Angeles, Los Angeles, California, United States

Loading trial locations.

About this study

The main purpose of the study is to compare the effects of two approaches on sleep and mood including any symptoms of depression and suicidality. There will be 420 people invited to participate across three sites in the United States (University of Pittsburgh, UCLA, Augusta).

Participants will be randomized to receive one of two evidence-based programs that are designed to help improve outcomes. Each group will contain 210 participants. Researchers will enroll a total of 140 participants (70 in each group) at the University of Pittsburgh. Both groups will meet with a study therapist once a week to complete the assigned 8-week program. To determine which (if any) program has beneficial effect over time, researchers will ask participants to complete assessments of their sleep, mood, and health before and after the therapy. Certain information regarding the nature of the interventions is withheld to protect the scientific integrity of the study design.

There are three main study visits where participants will complete assessments about their sleep, mood, cognition and health. These would be:

  • Before the therapy program begins
  • Right after it ends
  • Six months later

Around the time of each visit, researchers will ask participants to wear an actigraphy watch on their wrist 24/7 for a week while completing a sleep diary. The actigraphy watch is a wrist-watch like device that measures movement so that researchers can estimate the participant's activity and sleep levels.

After the first main visit is complete, participants will be randomly assigned to one of two programs that include meeting with a study clinician for 30-50 minutes each week for 8 weeks (8 sessions total). Both groups will receive educational information and, depending on the group the participants are assigned to, may include guided discussions, activities, and/or support addressing any stressors participants face, sleep problems, and/or depression.

During the therapy period, researchers would ask participants to continue wearing the actigraphy watch. Researchers would also ask participants to answer questions on the phone with study staff every other week, starting at week 2 (that would take about 30-40 minutes a week).

After the participant's last therapy session, researchers would repeat the phone assessments once a month until the last main visit occurs (six-months after therapy ends). Participants will have one more call at about 6 months after the last main visit (12 months after the therapy ended) to repeat some phone assessments done during the bi-weekly and monthly calls).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 55 Years and older
  • Patient Health Questionnaire -9 score of 10 or higher
  • Past month Scale for Suicide Ideation score of 3 or higher OR any history of suicide attempt
  • PROMIS Sleep Disturbance or impairment scale t-scores of 55 or higher
  • Pharmacotherapy for depression meeting minimum adequate dose level as defined by FDA approval documents for at least 4 weeks.

Exclusion criteria

  • Active suicide planning with intent or clinical judgement that suicide risk is too high for outpatient treatment OR being currently treated at an inpatient unit.
  • Bipolar disorder
  • Psychotic disorder
  • Borderline personality disorder.
  • Active Cognitive/Behavioral Therapy (e.g., CBT-I), current or upcoming esketamine (ketamine) treatment, or active phase of ECT/TMS treatment course.
  • Illness with life expectancy of less than 1 year or plans to leave the study area
  • Incapacity to consent/dementia diagnosis
  • Active substance use disorder of at least moderate severity
  • Active night-shift work
  • Any physical, mental, or neurological condition that would make participation in the study, including either treatment arm, unsafe or infeasible.

Treatment and study plan

Treatment as Usual

Other

In this trial, all participants will have depression symptoms and will be receiving TAU from their own doctors.

Active Condition

Behavioral

Participants receive eight ~40 minute sessions (one per week) with a therapist/health coach. Specific information regarding the nature of the interventions is withheld to protect the scientific integrity of the study design.

Active comparator

Behavioral

Participants receive eight ~40 minute sessions (one per week) with a therapist/health coach. Specific information regarding the nature of the interventions is withheld to protect the scientific integrity of the study design.

Primary outcomes

  1. Depression Symptom Response

    Time frame: six months post-treatment

    The outcome is the rate of clinically significant depression symptom responses six-months post treatment, defined as having ≥50% reduction in pre-treatment depression severity six-months posttreatment. Depression severity will be assessed as total scores from the 14 non-sleep items of the clinician rated GRID Hamilton Depression Rating Scale. Lower scores on the GRID Hamilton would indicate a reduction in depression symptoms.

Secondary outcomes

  1. Change in Suicide Ideation Severity

    Time frame: from Enrollment to the end of treatment at 6-months post-intervention

    Measuring rates of clinically significant past-month active SI at the six-month follow-up defined as Columbia Suicide Severity Rating Scale (CSSR) ideation dimension scores ≥ 3. This level on the CSSR, equivalent to having at least SI with a method, was identified as an optimal cut-off for predicting future suicide death. Lower scores on the Columbia Suicide Severity Rating Scale would indicate lower levels of suicide ideation.

  2. Suicide Behavior Outcomes

    Time frame: from Enrollment to the end of treatment at 6-months post-intervention

    Any suicidal behaviors over the six-month follow-up defined as escalating planning, suicide attempt, or suicide-related hospitalization.

Study contacts

Contact information is provided by the study sponsor or research team.

Sara Sellars, M.A

CONTACT

[email protected]

412-246-5963

Stephen Smagula, Ph.D

CONTACT

[email protected]

412-246-6674

Sponsors and collaborators

Lead sponsor

University of Pittsburgh

Other

Collaborators

  • Augusta University
  • Emory University
  • National Institute of Mental Health (NIMH)
  • National Institutes of Health (NIH)
  • University of California, Berkeley
  • University of California, Los Angeles

Registry information

Official study title

Multi-site Randomized Controlled Trial Comparing the Efficacy of Behavioral Approaches to Improve Mood and Sleep in Adults

Acronym: AIMS

Important dates

Study start
2025
Primary completion
2029
Study completion
2030
First posted
Oct 15, 2024
Registry last updated
May 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.